Literature DB >> 10454479

Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists.

B R Martin1, R Jefferson, R Winckler, J L Wiley, J W Huffman, P J Crocker, B Saha, R K Razdan.   

Abstract

Structure-activity relation studies have established that the alkyl side chain in tetrahydrocannabinol (THC) plays a crucial role in the activation of the cannabinoid receptor. Unfortunately, the flexible nature of this side chain has hampered efforts to elucidate the precise nature of the interaction of THC with its receptors. Therefore, a series of analogs with structurally restrained side chains of varying length was synthesized and evaluated for pharmacological potency in mice and for receptor affinity. The introduction of cis double bonds inserted rigid angles, whereas triple bonds developed regions of planarity. Receptor affinity for the acetylenic and saturated side chains were the same, whereas double bond substitution increased affinity 10-fold. Moreover, the relationship between receptor affinity and potency was 10-fold less than that of Delta(8)-THC in the case of some acetylenic derivatives, whereas changing the triple bond to a double bond restored the potency/affinity ratio. Additionally, an acetylene at C2-C3 in the octyl and nonyl side chains favored antinociception by as much as 70-fold. Surprisingly, several high-affinity acetylenic derivatives, especially those with cyano substitutions at the terminus of the side chain, were partial agonists or were inactive. Some of these low-efficacy, high-affinity ligands elicited antagonistic activity. The finding that manipulations of the side chain produces high- affinity ligands with either antagonist, partial agonist, or full agonist effects reveals a critical structural feature for receptor activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454479

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Authors:  Kathryn A Seely; Lisa K Brents; Anna Radominska-Pandya; Gregory W Endres; Gregory S Keyes; Jeffery H Moran; Paul L Prather
Journal:  Chem Res Toxicol       Date:  2012-03-15       Impact factor: 3.739

2.  The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.

Authors:  Peter J Crocker; Anu Mahadevan; Jenny L Wiley; Billy R Martin; Raj K Razdan
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

3.  Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation.

Authors:  Joong-Youn Shim; Alexander C Bertalovitz; Debra A Kendall
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

4.  Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.

Authors:  G Griffin; S Williams; M M Aung; R K Razdan; B R Martin; M E Abood
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Novel adamantyl cannabinoids as CB1 receptor probes.

Authors:  Ganesh A Thakur; Shama Bajaj; Carol Paronis; Yan Peng; Anna L Bowman; Lawrence S Barak; Marc G Caron; Demon Parrish; Jeffrey R Deschamps; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-05-14       Impact factor: 7.446

6.  Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.

Authors:  Jenny L Wiley; Valerie J Smith; Jianhong Chen; Billy R Martin; John W Huffman
Journal:  Bioorg Med Chem       Date:  2012-01-30       Impact factor: 3.641

7.  1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Authors:  Jenny L Wiley; Julie A Marusich; Billy R Martin; John W Huffman
Journal:  Drug Alcohol Depend       Date:  2011-11-27       Impact factor: 4.492

8.  Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Authors:  Jenny L Wiley; Christopher S Breivogel; Anu Mahadevan; Roger G Pertwee; Maria Grazia Cascio; Daniele Bolognini; John W Huffman; D Matthew Walentiny; Robert E Vann; Raj K Razdan; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2010-11-27       Impact factor: 4.432

9.  Novel, potent THC/anandamide (hybrid) analogs.

Authors:  Caryl Bourne; Sucharita Roy; Jenny L Wiley; Billy R Martin; Brian F Thomas; Anu Mahadevan; Raj K Razdan
Journal:  Bioorg Med Chem       Date:  2007-08-25       Impact factor: 3.641

10.  Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands.

Authors:  Dai Lu; Jianxin Guo; Richard I Duclos; Anna L Bowman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2008-10-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.